References
- Desai R, Oliveira LH, Parashar UD, et al. Reduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin America - a review. Mem Inst Oswaldo Cruz 2011;106(8):907-11
- de Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, et al. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. Pediatr Infect Dis J 2011;30(1 Suppl):S61-6
- Centers for Disease Control and Prevention (CDC). Progress in the introduction of rotavirus vaccine–Latin America and the Caribbean, 2006-2010. MMWR Morb Mortal Wkly Rep 2011;60(47):1611-4
- Linhares AC, Macias-Parra M, Sáez-Llorens X, et al. Rotavirus gastroenteritis in Latin America: a hospital-based study in children under 3 years of age. Trials Vaccinol 2012;1:36-41
- Perez Schael I, O’Ryan M, Sáez-Llorens X, et al. Clinical development, registration, and introduction of human rotavirus vaccine: the Latin American experience. Trials Vaccinol 2012;1:10-20
- Takemoto MLS, Bahia L, Toscano CM, Araujo DV. Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean. Vaccine 2013;31(Suppl 3):C45-576
- De Oliveira LH, Giglio N, Ciapponi A, et al. Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries. Vaccine 2013;31(Suppl 3):C99-108
- Khawaja S, Cardellino A, Klotz D, et al. Evaluating the health impact of a public-private partnership: to reduce rotavirus disease in Nicaragua. Hum Vaccin Immunother 2012;8(6):777-82
- Guardado JA, Clará W AW, Turcios RM, et al. Rotavirus in El Salvador: an outbreak, surveillance and estimates of disease burden, 2000-2002. Pediatr Infect Dis J 2004;23(10 Suppl):S156-60
- de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010;340:c282510
- Yen C, Armero Guardado JA, Alberto P, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011;30(1 Suppl):S6-S10
- Molto Y, Cortes JE, De Oliveira LH, et al. Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine. Pediatr Infect Dis J 2011;30(1 Suppl):S16-20
- Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. Int J Infect Dis 2012;16(2):e94-8
- Becker-Dreps S, Paniagua M, Zambrana LE, et al. Rotavirus prevalence in the primary care setting in Nicaragua after universal infant rotavirus immunization. Am J Trop Med Hyg 2011;85(5):957-6014
- Patel M, Pedreira C, De Oliveira LH, et al. Duration of protection of pentavalent rotavirus vaccination in Nicaragua. Pediatrics 2012;130(2):e365-72
- Cortes J, Arvelo W, Lopez B, et al. Rotavirus disease burden among children <5 years of age--Santa Rosa, Guatemala, 2007-2009. Trop Med Int Health 2012;17(2):254-916
- Solórzano Girón JO, Molina IB, Turcios-Ruiz RM, et al. Burden of diarrhea among children in Honduras, 2000-2004: estimates of the role of rotavirus. Rev Panam Salud Publica 2006;20(6):377-84
- Bourdett-Stanziola L, Jiménez C, Ortega-Barria E. Diversity of human rotavirus G and P genotypes in Panama, Costa Rica, and the Dominican Republic. Am J Trop Med Hyg 2008;79(6):921-4
- Bourdett-Stanziola L, Ortega-Barria E, Espinoza F, et al. Rotavirus genotypes in Costa Rica, Nicaragua, Honduras and the Dominican Republic. Intervirology 2011;54(1):49-52
- Quaye O, McDonald S, Esona MD, et al. Rotavirus G9P[4] in 3 countries in Latin America, 2009-2010. Emerg Infect Dis 2013;19(8):1332-20
- Khawaja S, Cardellino A, Mast TC. Hospital-based surveillance and analysis of genotype variation in Nicaragua after the introduction of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2014;33(1):e25-821